Saxenda & Victoza (Liraglutide) and Sex Drive: The Honest Evidence

Liraglutide is the older, once-daily GLP-1 — sold as Saxenda at 3.0 mg for weight management and as Victoza at up to 1.8 mg for type 2 diabetes. The sex-drive question people ask about it is the same one they ask about Ozempic and Zepbound: will this raise my libido, or flatten it? The honest answer is unchanged — no randomized trial of liraglutide has ever measured sexual desire as an endpoint, in men or women — but liraglutide has one feature that reshapes the framing. It produces less weight loss than the newer drugs: the pivotal SCALE Obesity and Prediabetes trial showed roughly 8% body-weight loss on liraglutide 3.0 mg^[13], well below Wegovy's ~15%^[8] and Zepbound's ~21%^[9]. Because libido changes on any GLP-1 run through weight loss (and, in men, testosterone), a smaller weight-loss lever means a more modest — but still real — effect. The daily-injection burden and lower potency are the honest trade-offs. This article covers both sexes: testosterone and the direct liraglutide-in-men signal, the PCOS-androgen wrinkle in women, and the early-nausea dip that a once-daily schedule spreads across the whole day. For the cross-drug picture, see our GLP-1 and libido hub; for the men's-anatomy side, our liraglutide and erectile dysfunction companion.

The honest summary

• No liraglutide trial has used libido or sexual desire as an endpoint. The SCALE program measured weight, glycemia, and cardiometabolic safety — not desire. Anyone quoting a precise “Saxenda libido number” is extrapolating from the weight-loss-to-sexual-function chain, not reading a trial result.
• Liraglutide is the smaller-weight-loss GLP-1. SCALE Obesity showed about −8% body weight on liraglutide 3.0 mg^[13], versus −14.9% for semaglutide 2.4 mg^[8] and −20.9% for tirzepatide 15 mg^[9]. Since libido effects are weight-loss-mediated, the honest expectation is a real but more modest benefit than the newer drugs.
• The effect is indirect and bidirectional. Libido on liraglutide moves through weight loss, testosterone, mood, energy, and body image — each of which can pull either way depending on the person and the phase of treatment. There is no proven direct receptor effect on desire.
• In men, the direct liraglutide signal points UP. Small studies adding liraglutide in obese hypogonadal men reported improved erectile function and sexual outcomes (Giagulli 2015^[5], La Vignera 2023^[4]) — consistent with the weight-loss-raises-testosterone chain (Camacho 2013 EMAS^[2], Corona 2013^[6]).
• In women, desire is less hormone-linear. The strongest data come from lifestyle weight-loss trials (Wing 2013 Look AHEAD^[10]) and a calorie-restriction RCT that directly measured sexual function (Martin 2016 CALERIE^[11]) — not from liraglutide itself. Improved mood and body image tend to help; aggressive restriction and fatigue can hurt.
• PCOS is the women-specific twist. Liraglutide lowers elevated androgens and improves the metabolic profile in polycystic ovary syndrome, which can blunt the androgen-driven part of desire in some women while raising overall satisfaction in others through better metabolic and psychological health.
• The once-daily schedule spreads the early dip across the day. Unlike the once-weekly drugs, liraglutide is injected every day, so nausea and appetite suppression are a daily rhythm during titration — the most likely window for a temporary drop in desire. Usually transient.
• A severe, persistent low libido that does not track the weight-loss process deserves a workup — a morning testosterone in men, a depression screen, a medication review (SSRIs are a common culprit), a thyroid check — not the assumption that “it is just the Saxenda.”

Why liraglutide is a different case from Ozempic or Zepbound

Liraglutide arrived years before semaglutide and tirzepatide, and it shows its age in two ways that matter for this discussion. First, it is once-daily rather than once-weekly — a subcutaneous injection every day, titrated from 0.6 mg up to 3.0 mg (Saxenda) over several weeks. Second, it is less potent for weight loss. The pivotal SCALE Obesity and Prediabetes trial (Pi-Sunyer 2015, NEJM^[13]) randomized adults with obesity or overweight-with-comorbidity to liraglutide 3.0 mg or placebo and reported roughly 8% body-weight loss at 56 weeks — a meaningful result for its era, but well short of what the newer molecules deliver.

That potency gap is the whole reason this article is not a copy of the semaglutide or tirzepatide reviews. If weight loss is the lever that moves libido — and the evidence says it is the dominant one — then liraglutide pulls that lever more gently. The mechanism is identical; the magnitude is smaller. A man losing 8% of his body weight will see a smaller testosterone rise than a man losing 15% or 21%; a woman's body-image and mood improvements scale with the weight lost. None of this creates a special liraglutide libido mechanism — it just means the weight-loss-mediated effects, good and bad, are more muted. The honest framing for a prospective Saxenda or Victoza user is: real but modest, and bought with a daily needle.

Why there is no direct answer (and why that is the honest framing)

Sexual desire is a brain phenomenon shaped by dopamine and reward circuitry, sex hormones (testosterone and estradiol), mood, sleep, energy, relationship context, and body image. GLP-1 receptors exist in the brain — part of how these drugs reduce appetite and “food noise” — but no trial of liraglutide, or of any GLP-1, has isolated a libido effect, positive or negative. So when you read “does Saxenda increase sex drive” or “does Victoza kill sex drive,” the accurate answer is that neither has been demonstrated as a direct drug action. What has been demonstrated is that losing weight changes the inputs to desire — testosterone, mood, erectile function, energy, confidence — and those changes run in opposite directions depending on where you are in treatment.

Men: the lever is testosterone

In men, the chain from weight loss to libido is relatively linear, and it is the best-supported part of the whole GLP-1-and-sex story. Adipose tissue expresses aromatase, which converts testosterone to estradiol, and obesity suppresses hypothalamic GnRH pulses — producing “obesity-associated functional hypogonadism” (Grossmann 2020^[7]). Weight loss reverses it:

1. Weight loss raises testosterone. The Corona 2013 meta-analysis^[6] found that body-weight loss reverts obesity-associated hypogonadotropic hypogonadism — low-calorie diets and bariatric surgery both raised total testosterone, with larger weight loss producing larger gains. The EMAS longitudinal cohort (Camacho 2013^[2]) showed weight loss blunts and can reverse the age-related testosterone decline, and testosterone tracks with body composition (Corona 2016^[12]).
2. The direct liraglutide signal in men is positive. This is where liraglutide actually has its own data rather than borrowing from semaglutide. Giagulli 2015 (Andrology^[5]) reported that adding liraglutide to lifestyle, metformin, and testosterone therapy in diabetic obese men with overt hypogonadism boosted erectile function. La Vignera 2023 (J Clin Med^[4]) found improved sexual and reproductive outcomes in obese men with functional hypogonadism treated with liraglutide. Both are small, but both point the same way.
3. Exercise and body composition reinforce it. Even structured exercise alone improved sexual function and testosterone in obese men (Khoo 2013^[3]), and the confidence that comes from erectile reliability and actual sexual experience feeds back into desire. The landmark Esposito 2004 JAMA trial^[1] showed lifestyle weight loss restored erectile function in about a third of obese men with ED.

The liraglutide-specific caveat: because SCALE weight loss is smaller^[13], the testosterone rise a man can expect is proportionally smaller than on semaglutide or tirzepatide. For most men who tolerate the daily injection and lose meaningful weight, the direction should still be neutral-to-improved once the early side effects pass. See the dedicated liraglutide and erectile dysfunction review and the broader GLP-1, testosterone, and male fertility evidence.

Women: desire is less hormonally linear

Female libido is shaped by mood, relationship context, body image, and energy more than by a single hormone, and the testosterone story does not map cleanly. There is no liraglutide sexual-function trial in women, so the evidence is borrowed from weight-loss studies. The Wing 2013 ancillary Look AHEAD study^[10] found that intensive lifestyle weight loss improved sexual function and reduced female sexual dysfunction in women with type 2 diabetes — randomized evidence that deliberate weight loss helps. The CALERIE 2 RCT (Martin 2016^[11]) measured sexual function under sustained calorie restriction in healthy women and men, a useful drug-neutral demonstration that an aggressive deficit itself — not just a drug — can affect sexual function in either direction.

The net picture for women on liraglutide: improved body image and mood from weight loss tend to raise desire, while the early nauseated, low-energy phase can lower it. Because liraglutide's weight loss is more modest^[13], the body-image-and-mood benefit is smaller than on the newer drugs, but the mechanism is the same. For the newer-drug comparisons, see semaglutide and sex drive in women and tirzepatide and sex drive in women.

PCOS and androgens: the women-specific complication

Polycystic ovary syndrome is where the liraglutide-and-libido question gets genuinely interesting, because PCOS is defined in part by elevated androgens, and androgens are part of what drives sexual desire. Liraglutide does not just cause weight loss in PCOS — it measurably shifts the hormonal profile, lowering elevated testosterone, raising SHBG, and improving ovulation alongside the weight loss. That hits libido in two competing directions, and which one wins is individual:

1. Androgen normalization could blunt the androgen-driven part of desire in some women. If baseline testosterone is high because of PCOS, bringing it toward normal removes one input to sexual desire. A minority of women may notice a softening of libido as androgens fall — a plausible, mechanism-based expectation, not a measured trial result.
2. Improved metabolic and psychological health often raises desire. PCOS itself is associated with more sexual dysfunction, tied to hirsutism, body image, mood, and metabolic burden. Treating those drivers can raise overall sexual satisfaction even as androgens normalize.

The net effect in any individual woman is unpredictable from the literature, because no liraglutide trial measured libido as an endpoint in this population. The reasonable expectation is that improved confidence, mood, and metabolic health usually dominate — but a woman who notices reduced desire as her androgens fall is not imagining it, and it is worth raising with her clinician. For the full picture, see our PCOS and GLP-1 evidence review.

The early dip: nausea, fatigue, and the once-daily rhythm

The first weeks of liraglutide — the daily dose escalation from 0.6 mg toward 3.0 mg on Saxenda — are the most likely window for a temporary drop in desire, and the reason is mundane rather than hormonal. A body in an aggressive energy-deficit and nauseated state is not primed for sexual interest. The CALERIE 2 data^[11] confirm the deficit itself can affect sexual function independent of any specific drug. A few honest points, with a liraglutide-specific wrinkle:

• Once-daily spreads the effect across the day. Unlike the once-weekly drugs, whose nausea can cluster around dosing day, liraglutide's daily injection means appetite suppression and any GI symptoms are a steady daily rhythm. For some people that is gentler; for others it is a constant low-grade drag during titration.
• This is usually transient. GI side effects typically peak during dose escalation and ease as the body adapts and the dose stabilizes. Libido that dipped during titration commonly recovers.
• It is not a sign the drug is permanently “killing” your sex drive. A titration-phase dip is a comfort-and-energy effect, not evidence of a lasting libido-suppressing mechanism.
• Pace the escalation with your prescriber. If side effects are intense, a slower liraglutide escalation is often the fix, and adequate protein and hydration help prevent the fatigue that suppresses desire.

Is the low libido the drug, or the weight-loss process?

This is the most useful question to ask, because the answer changes what you do about it:

• If the dip is early and tracks your side effects — worst when you are most nauseated and fatigued, easing as you adapt and the dose stabilizes — it is most likely the process, not a fixed drug effect.
• If desire improves as you lose weight and feel better, that is the common trajectory, and the mechanisms (testosterone in men^[2][6], mood and body image in both sexes) are well supported — just at a smaller magnitude on liraglutide given the more modest weight loss^[13].
• If the low libido is severe, persistent, and detached from how you otherwise feel, do not write it off as “just the Saxenda.” That pattern warrants a workup: a morning total testosterone (men), a depression and anxiety screen, a medication review (SSRIs are a leading cause of low libido), a thyroid check, and a sleep assessment.

Practical guidance

• Set the expectation correctly. The realistic forecast on liraglutide is “no change or a modest gradual improvement once weight loss takes hold, with a possible dip during the rough early weeks” — a smaller version of the newer-drug pattern, because the weight loss is smaller^[13].
• Give the early phase time. A drive that dips while you are nauseated and adapting is the most common and most self-limited scenario. Reassess once the daily dose has stabilized.
• Protect energy and lean mass. Adequate protein and resistance training preserve lean mass, which supports testosterone and energy — both of which feed libido. Do not under-eat protein just because appetite is low.
• Men: confirm testosterone the right way. If libido stays low, get a morning total testosterone on a confirmatory draw before assuming anything — weight loss often raises it (Corona 2013^[6]), so functional hypogonadism may be reversing rather than worsening.
• Review your other medications. SSRIs, some beta-blockers, finasteride, and certain antipsychotics lower libido and may be the bigger driver than the GLP-1.
• Do not stop liraglutide on your own to “test” it. Talk to your prescriber — dose timing, anti-nausea support, and addressing a concurrent medication or mood issue often resolve the problem without abandoning the benefit.

What we still don't know

• No published liraglutide trial has used libido, the FSFI, or any validated sexual-function instrument as a pre-specified endpoint. The entire picture is assembled from weight-loss-and-sexual-function studies and small direct signals in men.
• The net libido effect of androgen normalization in PCOS has not been directly measured for liraglutide. The two competing directions have not been disentangled in a sexual-function endpoint.
• Whether liraglutide's smaller weight loss^[13] translates into a proportionally smaller libido benefit, or whether a threshold of weight loss matters more than the exact percentage, is unstudied.
• A potential direct effect of GLP-1 signaling on sexual physiology, independent of weight loss, has not been characterized for liraglutide.

Bottom line

• No randomized trial has measured sexual desire as an endpoint for liraglutide (Saxenda, Victoza). Claims of a precise libido effect are extrapolation.
• Liraglutide is the older, once-daily, smaller-weight-loss GLP-1 — about 8% in SCALE^[13] versus ~15%^[8] and ~21%^[9] for the newer drugs. Because libido effects are weight-loss-mediated, the honest expectation is real but more modest, bought with a daily injection.
• In men the lever is testosterone (rises with weight loss^[2][6]), and the small direct liraglutide signals are positive^[4][5]. In women, desire is less hormonally linear and shaped more by mood, energy, and body image, with a PCOS-androgen wrinkle.
• Early daily-titration nausea and fatigue can transiently dampen desire — usually temporary, and a comfort-and-energy effect rather than a permanent libido-suppressing mechanism.
• A severe, persistent low libido that does not track the weight-loss process deserves a workup — testosterone, depression screen, medication review, thyroid — not the assumption that “it is just the Saxenda.”

Related research

• Liraglutide and erectile dysfunction — the men's-anatomy companion to this article, covering the vascular-ED-and-weight-loss chain
• GLP-1s and libido: the cross-drug evidence hub — the master overview spanning men and women, semaglutide and tirzepatide
• Semaglutide and sex drive in women — the Ozempic/Wegovy female-libido review
• Tirzepatide and sex drive in women — the Zepbound/Mounjaro female-libido review
• GLP-1s and erectile dysfunction — the full weight-loss-and-ED evidence review
• Weight loss reverses ED — the mechanism and RCT evidence for erectile-function recovery
• GLP-1s, testosterone, and male fertility — how weight loss moves testosterone in men
• GLP-1s and PCOS — the full polycystic ovary syndrome evidence review

Important disclaimer. This article is educational and does not constitute medical advice. There is no randomized-trial evidence of a direct liraglutide effect on libido; the discussion here describes indirect mechanisms supported by the weight-loss and sexual-function literature. A new, severe, or persistent change in sexual desire warrants evaluation by a clinician, including a morning total testosterone in men, a depression and anxiety screen, a medication review, and a thyroid assessment. Liraglutide is not recommended during pregnancy and should be discontinued in advance of a planned pregnancy. Do not start, stop, or change any prescription medication based on this article. PMIDs were independently verified against the PubMed E-utilities API on 2026-06-30.

Last verified: 2026-06-30. Next review: every 12 months, or sooner if a randomized liraglutide trial with a pre-specified sexual-desire endpoint is published.